Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C

Journal of Hepatology

Volumn 34, Issue 5, 2001, Pages 730-739

  Poynard, Thierry ^a   Ratziu, Vlad ^a   Charlotte, Frédéric ^a   Goodman, Zachary ^b   McHutchison, John ^c   Albrecht, Janice ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; GENDER; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AGING; ALCOHOL DRINKING; BLOOD TRANSFUSION; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX CHARACTERISTICS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0035009810     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)00097-0     Document Type: Article

References (37)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology. 26:(Suppl 1):1997;62-65.
2. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 72:1997;341-344.
3. Tong M.J., el-Farra N.S., Reikes A.R., Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
4. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349:1997;825-832.
5. Consensus Statement. EASL International Consensus Conference on Hepatitis C. J Hepatol. 30:1999;956-961.
6. Pagliaro L., Peri V., Linea C., Camma C., Giunta M., Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol. 31:1999;28-44.
7. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 340:1999;1228-1233.
8. Datz C., Cramp M., Haas T., Dietze O., Nitschko H., Froesner G., et al. The natural course of hepatitis C virus infection 18 years after an epidemic out break of non-A, non-B hepatitis in a plasmapheris centre. Gut. 44:1999;563-567.
9. Chossegros P., Pradat P., Bailly F., Chemello L., Sauleda S., Saracco G., et al. Natural history of chronic hepatitis C: fibrosis progression is not linear. J Hepatol. 30:(Suppl 1):1999;52.
10. Observatoire national de l'hépatite C: bilan inital. Association Française pour l'Etude du Foie. Gastroenterol Clin Biol. 1995;81.
11. Cacoub P., Poynard T., Ghillani P., Charlotte F., Olivi M., Piette J.C., et al. Extrahepatic manifestations in patients with chronic hepatitis C. Rheum Arthr. 42:1999;2204-2212.
12. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Idio G., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
13. McHutshison J., Gordon S., Schiff E., Shiffman M.L., Lee W.M., Rustgki V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as intial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
14. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology. 20:1994;15-20.
15. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 24:1996;289-293.
16. Hintze J.L. NCSS 97 User guide. Number cruncher statistical systems. Kaysville, UT. 1997.
17. Tong M.J., Hwang S.J., Lefkowitz, Lee S.D., Co R.L., Conrad S.A., et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol. 9:1994;587-591.
18. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B. Typing of hepatitis C virus isolates and characterisation of new subtypes using a line probe assay. J Gen Virol. 74:1993;1093-1102.
19. Poynard T., Bedossa P., Chevalier M., Mathurin P., Lemonier C., Trepo C., et al. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non A, non B hepatitis. New Engl J Med. 332:1995;1457-1462.
20. Fang J.W., Albrecht J.K., Jacobs S., Lau J.Y. Quantification of serum hepatitis C virus RNA. Hepatology. 29:1999;997-998.
21. Sobesky R., Mathurin P., Charlotte F., Meussalli J., Olivi M., Viduud M., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology. 116:1999;378-386.
22. Deuffic S., Buffat L., Poynard T., Valleron A.J. Modeling the hepatitis C virus epidemic in France. Hepatology. 29:1999;1596-1601.
23. Goodson J.D., Taylor P.A., Campion E.W., Richter J.N., Wands J. The clinical course of acute hepatitis in the ederly patient. Arch Intern Med. 142:1982;1485-1488.
24. Wynne H.A., Cope L.H., Mutch E., Rawlins M.D., Woodhouse K.W., James O.F., et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 9:1989;297-301.
25. Nagel J.E., Chrest J.J., Adler H.H. Enumeration of T lymphocytes by monoclonal antibodies in young age and aged humans. J Immunol. 191:(151):1991;599-603.
26. Makinodan T., Kay M.M.B. Age influence on the immune system. Adv Immunol. 29:1980;287-291.
27. Poynter M.E., Daynes R.A. Peroxysome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 273:1998;32833-32841.
28. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inoue O., et al. The long term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
29. Roudot-Thoraval F., Bastie A., Pawlotsky J.M., Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. The Study Group for the Prevalence and Epidemiology of Hepatitis C Virus. Hepatology. 26:1997;485-490.
30. Bissell D.M. Sex and hepatic fibrosis. Hepatology. 29:1999;988-989.
31. Yasuda M., Shimizu I., Shiba M., Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology. 29:1999;719-727.
32. Ashcroft G.S., Dodsworth J., van Boxtel E., Tarnuzzer R.W., Moran M.A., Schultz G.S., et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta 1 levels. Nat Med. 3:1997;1209-1215.
33. Wang Y.J., Wang S.S., Bickel M., Guenzler V., Gerl M., Bissell D.M. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathology. 152:1998;279-287.
34. Bentzen S.M., Skoczylas J.Z., Overgaard M., Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Nat Cancer Inst. 88:1996;918-922.
35. Roffi L., Ricci A., Ogliari C., Scalori A., Minola E., Colloredo G., Chemello M., Colloredo G., Di Stefano R. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol. 29:1998;701-706.
36. Pontisso P., Bellati G., Brunetto M., Chemello M., Colloredo G., Di Stefano R., et al. Hepatitis C RNA virus profiles in chronically infected individuals: do they relate to disease activity? Hepatology. 29:1999;585-589.
37. Paradis V., Mathurin P., Laurent A., Charlotte F., Vidaud M., Poynard T., et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol. 49:1996;998-1004.